Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: $PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PDS Biotechnology Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PDS Biotechnology Corporation's position in the market.
Rhea-AI Summary
PDS Biotechnology Corporation appoints Dr. Kirk V. Shepard as Chief Medical Officer, bringing over 30 years of experience in the pharmaceutical industry. Dr. Shepard's expertise will be crucial as the company transitions from clinical development research to regulatory strategy and commercialization for their lead targeted cancer immunotherapy candidates. The company also granted Dr. Shepard 200,000 stock options as a material inducement to his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
-
Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announced its participation in the B. Riley Securities 4th Annual Oncology Conference, where the President and CEO, Frank Bedu-Addo, will be part of a fireside chat. The event will focus on finding value in (Near-) Commercial Oncology Companies. PDS Biotech is a clinical-stage immunotherapy company developing cancer immunotherapies and infectious disease vaccines based on its proprietary T cell activating platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
-
Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) granted 200,000 nonstatutory stock options to Lars Boesgaard, the new Chief Financial Officer. The stock option has an exercise price of $5.28 and vests over a four-year period, subject to continued employment with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary
PDS Biotechnology Corporation (PDSB) announces the appointment of Lars Boesgaard as Chief Financial Officer, effective December 4, 2023. Boesgaard brings over 25 years of healthcare experience and has previously served as CFO of AM-Pharma B.V. and Columbia Care. He holds a Bachelor of Science in Business Administration from the Copenhagen Business School and a Master of Business Administration from the Richard Ivey School of Business, Western University, Ontario, Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
-
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced positive results from multiple clinical trials, including a 75% survival rate at 36 months in the NCI-led Phase 2 combination trial for advanced HPV16-positive cancer patients, and a 74% 2-year overall survival rate in the VERSATILE-002 Phase 2 trial for HPV16-positive head and neck cancer patients. The company also reported promising interim safety and immune response data for a Phase 1/2 clinical trial for metastatic prostate cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.55%
Tags
-
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301, and an investigational immune checkpoint inhibitor (ICI) in advanced cancer patients with HPV16-positive cancers. The trial showed 75% of ICI naïve patients remaining alive at 36 months, with a 12-month survival rate of 72% in ICI resistant patients. PDS0101 plus high doses of ICI and PDS0301 achieved an overall response rate of 63%, while the ORR for PDS0101 plus low doses of ICI and/or PDS0301 was 5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
News
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) will release its financial results for the third quarter of 2023 on November 14, 2023, before the market opens. A conference call will follow to review the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
-
Rhea-AI Summary
PDS Biotechnology announces immune response data from a Phase 2 clinical trial of PDS0101 in combination with KEYTRUDA in HPV-positive head and neck cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
-
Rhea-AI Summary
PDS Biotech announces positive interim data for Phase 1/2 clinical trial evaluating PDS0301 in combination with docetaxel for metastatic prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
Rhea-AI Summary
PDS Biotech announces interim data from VERSATILE-002 trial for head and neck cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.47%
Tags
PDS Biotechnology Corporation
Nasdaq:PDSB
PDSB Rankings
PDSB Stock Data
128.01M
35.41M
3.67%
22.93%
16.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
PRINCETON
About PDSB
pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati